Status:
COMPLETED
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Lead Sponsor:
Pfizer
Conditions:
Pancreatic Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2 study being conducted at multiple centers in the United States, Europe and Canada. Patients having pancreatic cancer that is locally advanced or that has spread to other parts of the...
Eligibility Criteria
Inclusion
- patients with advanced (localized but surgically unresectable or metastatic) histologically/cytologically proven epithelial cancer of the exocrine pancreas
- no prior therapy for metastatic disease
Exclusion
- patients with locally advanced disease who are candidates for radiation therapy.
- uncontrolled brain metastases (a controlled brain metastasis must be previously treated, asymptomatic, and without growth for 4 months)
Key Trial Info
Start Date :
July 5 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 14 2008
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00219557
Start Date
July 5 2005
End Date
March 14 2008
Last Update
May 14 2019
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
East Bay Medical Oncology/Hematology Medical Associates Inc.
Antioch, California, United States, 94509
2
Alta Bates Comprehensive Cancer Center
Berkeley, California, United States, 94704
3
Bay Area Cancer Research Group
Concord, California, United States, 94520
4
East Bay Medical Oncology/Hematology Medical Associates, Inc.
Concord, California, United States, 94520